Conditions: Colorectal Neoplasms
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 768
Healthy volunteers: no

Brief summary:
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Nintedanib (BIBF 1120) intervention 2: Placebo intervention 3: BSC intervention 4: BSC
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document: